Biohaven completes enrolment in opakalim RISE 3 epilepsy study

ADC Therapeutics completes enrolment in Phase 1b ZYNLONTA combination trial

Sanofi reports positive phase 3 results for Nexviazyme in infantile-onset Pompe disease

Zelluna awarded NOK16m research grant for Phase 1 cancer study

AMR Clinical acquires ClinOhio Research Services

Nuvation Bio's taletrectinib Marketing Authorisation Application for advanced ROS1-positive non-small cell lung cancer treatment validated in UK

Viatris announces VR-205 Phase 3 Study results in Japanese adults with primary immunoglobulin A nephropathy

Grünenthal completes Nociceptin Receptor (NOP) Agonist Phase I trial

Natera and Aveta Biomics partner on Phase 3 head and neck cancer trial

AbbVie receives positive CHMP opinion for upadacitinib in severe alopecia areata

Neurogene reports durable positive long-term results from NGN-401 gene therapy in Rett syndrome trial

Evommune reports Phase 2b trial miss for EVO756 in chronic spontaneous urticaria

AbbVie receives positive CHMP opinion for upadacitinib in non‑segmental vitiligo

AstraZeneca's Datroway recommended for EU approval as first-line treatment in metastatic triple-negative breast cancer

Nippon Shinyaku and Elixirgen Therapeutics enter option agreement for development and commercialisation of EXG-7001 for Duchenne Muscular Dystrophy